Urolithin D (Standard)

Urolithin D (Standard) (3,4,8,9-Tetrahydroxy urolithin (Standard) ) is the analytical standard of Urolithin D (HY-133178) . This product is intended for research and analytical applications. Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC50 of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases[1].

Product Specifications

CAS Number

[131086-98-1]

Product Name Alternative

3,4,8,9-Tetrahydroxy urolithin (Standard)

UNSPSC

12352005

Target

AMPK; Ephrin Receptor; PPAR; Reference Standards

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Others; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Smiles

O=C1C2=CC(O)=C(O)C=C2C3=CC=C(O)C(O)=C3O1

Molecular Formula

C13H8O6

Molecular Weight

260.20

References & Citations

[1]Giorgio C, et al. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol Nutr Food Res. 2015 Nov;59 (11) :2155-67.